Online inquiry

IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ9023MR)

This product GTTS-WQ9023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MST1R gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	2-Thio-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001244937.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	4486
UniProt ID	Q04912

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9023MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ1190MR	IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	ABP 980
GTTS-WQ5181MR	IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CAT-354
GTTS-WQ1814MR	IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	AFD Anti-fD
GTTS-WQ13135MR	IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	PF-04360365
GTTS-WQ1360MR	IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	ABT-874
GTTS-WQ485MR	IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	42-89-glycoprotein
GTTS-WQ14706MR	IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	SEG101
GTTS-WQ1389MR	IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ABT-981

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST